Positive Media Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price

News coverage about ContraFect (NASDAQ:CFRX) has been trending positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ContraFect earned a news impact score of 0.29 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.4724413749036 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

NASDAQ:CFRX traded up $0.05 on Friday, hitting $1.63. 53,880 shares of the company’s stock were exchanged, compared to its average volume of 234,592. ContraFect has a 52 week low of $0.80 and a 52 week high of $2.40. The stock has a market capitalization of $119.71, a PE ratio of -4.39 and a beta of -0.62.

How to Become a New Pot Stock Millionaire

ContraFect (NASDAQ:CFRX) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04. research analysts expect that ContraFect will post -0.36 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Positive Media Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price” was reported by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/04/01/contrafect-cfrx-given-coverage-optimism-score-of-0-29/1998364.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.